Аспарагиназа является одним из важнейших химиотерапевтических средств против острого лимфобластного лейкоза — наиболее распространённой формы рака крови. На сегодняшний день обе используемые в гематологии аспарагиназы из Escherichia coli и Dickeya dadantii (ранее известная как Erwinia chrysanthemi) индуцируют химиорезистентность у раковых клеток и побочные эффекты в виде гиперчувствительности иммунных реакций. Лейкозные клетки могут быть не восприимчивыми к аспарагиназе из-за повышенной активности аспарагинсинтетазы и других механизмов, связанных с устойчивостью к аспарагиназе. Поэтому поиск новых продуцентов L-аспарагиназ с улучшенными фармакологическими свойствами остается перспективным и актуальным направлением. В данной работе рассмотрены механизмы развития резистентности и лекарственной устойчивости к L-аспарагиназе, а также возможные пути их преодоления.
Александрова С.С., Гладилина Ю.А., Покровская М.В., Соколов Н.Н., Жданов Д.Д. (2022) Механизмы развития побочных эффектов и лекарственной устойчивости к аспарагиназам и пути их преодоления. Биомедицинская химия, 68(2), 104-116.
Александрова С.С. и др. Механизмы развития побочных эффектов и лекарственной устойчивости к аспарагиназам и пути их преодоления // Биомедицинская химия. - 2022. - Т. 68. -N 2. - С. 104-116.
Александрова С.С. и др., "Механизмы развития побочных эффектов и лекарственной устойчивости к аспарагиназам и пути их преодоления." Биомедицинская химия 68.2 (2022): 104-116.
Александрова, С. С., Гладилина, Ю. А., Покровская, М. В., Соколов, Н. Н., Жданов, Д. Д. (2022). Механизмы развития побочных эффектов и лекарственной устойчивости к аспарагиназам и пути их преодоления. Биомедицинская химия, 68(2), 104-116.
Переводная версия в журнале «Biomedical Chemistry (Moscow) Supplement Series B»:10.1134/S1990750822030027
Список литературы
Pokrovsky V.S., Chepikova O.E., Davydov D.Z., Zamyatnin A.A. Jr., Lukashev A.N., Lukasheva E.V. (2019) Amino acid degrading enzymes and their application in cancer therapy. Curr. Med. Chem., 26, 446-464. CrossRef Scholar google search
Beckett A., Gervais D. (2019) What makes a good new therapeutic L-asparaginase? World J. Microbiol. Biotechnol., 35, 152. CrossRef Scholar google search
Dinndorf P.A., Gootenberg J., Cohen M.H., Keegan P., Pazdur R. (2007) FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist, 12, 991-998. CrossRef Scholar google search
Jaccard A., Petit B., Girault S., Suarez F., Gressin R., Zini J.-M., Coiteux V., Larroche C., Devidas A., Thiéblemont C., Gaulard P., Marin B., Gachard N., Bordessoule D., Hermine O. (2009) L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 20, 110-116. CrossRef Scholar google search
Völler S., Pichlmeier U., Zens A., Hempel G. (2018) Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia. Cancer Chemother. Pharmacol., 81, 305-314. CrossRef Scholar google search
Chien W.-W., Allas S., Rachinel N., Sahakian P., Julien M., Le Beux C., Lacroix C.-E., Abribat T., Salles G. (2014) Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. Invest. New Drugs., 32, 795-805. CrossRef Scholar google search
Sharma D., Singh K., Singh K., Mishra A. (2018) Insights into the microbial L-asparaginases: from production to practical applications. Curr. Protein Pept. Sci., 20, 452-464. CrossRef Scholar google search
Lubkowski J., Vanegas J., Chan W.-K., Lorenzi P.L., Weinstein J.N., Sukharev S., Fushman D., Rempe S., Anishkin A., Wlodawer A. (2020) Mechanism of catalysis by L-asparaginase. Biochemistry, 59, 1927-1945. CrossRef Scholar google search
Ghasemian A., Al-Marzoqi A.H., Al-Abodi H.R., Alghanimi Y.K., Kadhum S.A., Shokouhi Mostafavi S.K., Fattahi A. (2019) Bacterial L-asparaginases for cancer therapy: current knowledge and future perspectives. J. Cell. Physiol., 234, 19271-19279. CrossRef Scholar google search
Batool T., Makky E.A., Jalal M., Yusoff M.M. (2016) A comprehensive review on L-asparaginase and its applications. Appl. Biochem. Biotechnol., 178, 900-923. CrossRef Scholar google search
Michalska K., Jaskolski M. (2006) Structural aspects of L-asparaginases, their friends and relations. Acta Biochim. Pol., 53, 627-640. Scholar google search
Niu J., Meng F., Zhou Y., Zhang C., Lu Z., Lu F., Chen M. (2021) Non-classical secretion of a type I L-asparaginase in Bacillus subtilis. Int. J. Biol. Macromol., 180, 677-683. CrossRef Scholar google search
Yao M., Yasutake Y., Morita H., Tanaka I. (2005) Structure of the type I L-asparaginase from the hyperthermophilic archaeon Pyrococcus horikoshii at 2.16 angstroms resolution. Acta Crystallogr. D. Biol. Crystallogr., 61, 294-301. CrossRef Scholar google search
Jiao L., Chi H., Lu Z., Zhang C., Chia S.R., Show P.L., Tao Y., Lu F. (2020) Characterization of a novel type I L-asparaginase from Acinetobacter soli and its ability to inhibit acrylamide formation in potato chips. J. Biosci. Bioeng., 129, 672-678. CrossRef Scholar google search
Sharafi Z., Barati M., Khoshayand M.R., Adrangi S. (2017) Screening for type II L-asparaginases: lessons from the genus halomonas. Iran. J. Pharm. Res. IJPR., 16, 1565-1573. Scholar google search
Nowak-Gottl U., Wolff J.E.A., Kuhn N., Boos J., Kehrel B., Lilienweiss V., Schwabe D., Jürgens H. (1994) Enhanced thrombin generation, P-von willebrand factor, P-fibrin D-dimer and P-plasminogen activator inhibitor 1: Predictive for venous thrombosis in asparaginase-treated children. Fibrinolysis, 8, 63-65. CrossRef Scholar google search
Leibundgut K., Hirt A., Zwicky C., Wuillemin W.A. (2003) Cerebral sinovenous thrombosis during asparaginase treatment. Case 3. Hamostaseologie, 23, 109-112. CrossRef Scholar google search
Fonseca M.H.G., Fiúza T.D.S., de Morais S.B., de Souza C.B., Trevizani R. (2021) Circumventing the side effects of L-asparaginase. Biomed. Pharmacother., 139, 111616. CrossRef Scholar google search
da Silva Lacerda G.R., Cantalice J.C.L.L., de Souza Lima G.M., de Albuquerque L.E.F., da Silva I.D.G., de Melo M.E.B., Adam M.L., do Nascimento S.C. (2019) Genotoxic activity of L-asparaginase produced by Streptomyces ansochromogenes UFPEDA 3420, World J. Microbiol. Biotechnol., 35, 41. CrossRef Scholar google search
Aghaiypour K., Wlodawer A., Lubkowski J. (2001) Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase, Biochemistry, 40, 5655-5664. CrossRef Scholar google search
Kessel D. (1971) Asparaginyl-transfer RNA. A substrate for L-asparaginase, BBA Sect. Nucleic Acids Protein Synth., 240, 554-557. CrossRef Scholar google search
Bosmann H.B., Kessel D. (1970) Inhibition of glycoprotein synthesis in L5178Y mouse leukaemic cells by L-asparaginase in vitro. Nature, 226, 850-851. CrossRef Scholar google search
Ankel E.G., Zirneski J., Ring B.J., Holcenberg J.S. (1984) Effect of asparaginase on cell membranes of sensitive and resistants mouse lymphoma cells. In Vitro, 20, 376-384. CrossRef Scholar google search
Zhdanov D.D., Pokrovsky V.S., Pokrovskaya M.V., Alexandrova S.S., Eldarov M.A., Grishin D.V., Basharov M.M., Gladilina Y.A., Podobed O.V., Sokolov N.N. (2017) Inhibition of telomerase activity and induction of apoptosis by Rhodospirillum rubrum L-asparaginase in cancer Jurkat cell line and normal human CD4+ T lymphocytes. Cancer Med., 6, 2697-2712. CrossRef Scholar google search
Plyasova A.A., Pokrovskaya M.V., Lisitsyna O.M., Pokrovsky V.S., Alexandrova S.S., Hilal A., Sokolov N.N., Zhdanov D.D. (2020) Penetration into cancer cells via clathrin-dependent mechanism allows L-asparaginase from Rhodospirillum rubrum to inhibit telomerase. Pharmaceuticals, 13, 286. CrossRef Scholar google search
Kidd J.G., Sobin L.H. (1966) The incorporation of L-asparagine-14C by lymphoma 6C3HED cells: its inhibition by guinea pig serum. Cancer Res., 26, 208-211. Scholar google search
Kidd J.G. (1953) Regression of transplanted lymphomas induced in vivo by means of normal guinea-pig serum: I. Course of transplanted cancer of various kinds in mice and rats given guinea-pig serum, horse serum or rabbit serum. J. Exp. Med., 98, 565-582. CrossRef Scholar google search
Broome J.D. (1965) Antilymphoma activity of L-asparaginase in vivo: clearance rates of enzyme preparations from guinea pig serum and yeast in relation to their effect on tumor growth. J. Natl. Cancer Inst., 35, 967-974. Scholar google search
Ponomarenko J., Papangelopoulos N., Zajonc D.M., Peters B., Sette A., Bourne P.E. (2011) IEDB-3D: structural data within the immune epitope database. Nucleic Acids Res., 39, D1164-D1170. CrossRef Scholar google search
Covini D., Tardito S., Bussolati O., Chiarelli L.R., Pasquetto M.V., Digilio R., Valentini G., Scotti C. (2012) Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat. Anticancer. Drug Discov., 7, 4-13. CrossRef Scholar google search
Cantor J.R., Panayiotou V., Agnello G., Georgiou G., Stone E.M. (2012) Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer. Methods Enzymol., 502, 291-319. CrossRef Scholar google search
Hermanova I., Zaliova M., Trka J., Starkova J. (2012) Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase. Exp. Hematol. 40, 657-665. CrossRef Scholar google search
Hawkins D.S., Park J.R., Thomson B.G., Felgenhauer J.L., Holcenberg J.S., Panosyan E.H., Avramis V.I. (2004) Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin. Cancer Res., 10, 5335-5341. CrossRef Scholar google search
Krishnapura P.R., Belur P.D., Subramanya S. (2016) A critical review on properties and applications of microbial L-asparaginases. Crit. Rev. Microbiol., 42, 720-737. CrossRef Scholar google search
Yamaguchi M., Kwong Y.-L., Kim W.S., Maeda Y., Hashimoto C., Suh C., Izutsu K., Ishida F., Isobe Y., Sueoka E., Suzumiya J., Kodama T., Kimura H., Hyo R., Nakamura S., Oshimi K., Suzuki R. (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J. Clin. Oncol., 29, 4410-4416. CrossRef Scholar google search
Wang L., Wang Z., Chen X., Li Y., Wang K., Xia Y., Xia Z. (2013) First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer, 119, 348-355. CrossRef Scholar google search
Jaccard A., Gachard N., Marin B., Rogez S., Audrain M., Suarez F., Tilly H., Morschhauser F., Thieblemont C., Ysebaert L., Devidas A., Petit B., de Leval L., Gaulard P., Feuillard J., Bordessoule D., Hermine O., GELA and GOELAMS Intergroup (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood, 117, 1834-1839. CrossRef Scholar google search
Li X., Cui Y., Sun Z., Zhang L., Li L., Wang X., Wu J., Fu X., Ma W., Zhang X., Chang Y., Nan F., Li W., Su L., Wang J., Xue H., Zhang M. (2016) DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin. Cancer Res., 22, 5223-5228. CrossRef Scholar google search
Hijiya N., van der Sluis I.M. (2016) Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk. Lymphoma, 57, 748-757. CrossRef Scholar google search
Avramis V.I., Avramis E.V., Hunter W., Long M.C. (2009) Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res., 29, 299-302. Scholar google search
Rajić V., Debeljak M., Goričar K., Jazbec J. (2015) Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia. Leuk. Lymphoma, 56, 3103-3108. CrossRef Scholar google search
Cantor J.R., Yoo T.H., Dixit A., Iverson B.L., Forsthuber T.G., Georgiou G. (2011) Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc. Natl. Acad. Sci. USA, 108, 1272-1277. CrossRef Scholar google search
Moola Z.B., Scawen M.D., Atkinson T., Nicholls D.J. (1994) Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem. J., 302, Pt 3 921-927. CrossRef Scholar google search
Offman M.N., Krol M., Patel N., Krishnan S., Liu J., Saha V., Bates P.A. (2011) Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood, 117, 1614-1621. CrossRef Scholar google search
Jianhua C., Yujun W., Ruibo J., Min W., Wutong W. (2006) Probing the antigenicity of E. coli L-asparaginase by mutational analysis. Mol. Biotechnol., 33, 57-65. CrossRef Scholar google search
Werner A., Röhm K.-H., Müller H.-J. (2005) Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment., Biol. Chem. 386, 535-540. CrossRef Scholar google search
Mehta R.K., Verma S., Pati R., Sengupta M., Khatua B., Jena R.K., Sethy S., Kar S.K., Mandal C., Roehm K.H., Sonawane A. (2014) Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice. J. Biol. Chem., 289, 3555-3570. CrossRef Scholar google search
Zeidan A., Wang E.S., Wetzler M. (2009) Pegasparaginase: where do we stand? Expert Opin. Biol. Ther., 9, 111-119. CrossRef Scholar google search
Medawar C.V., Mosegui G.B.G., de M. Vianna C.M., da Costa T.M.A. (2019) PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review. Hematol. Transfus. Cell Ther., 42, 54-61. CrossRef Scholar google search
Pokrovsky V.S., Kazanov M.D., Dyakov I.N., Pokrovskaya M.V., Aleksandrova S.S. (2016) Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases. BMC Cancer, 16, 89. CrossRef Scholar google search
Pokrovskaya M.V., Aleksandrova S.S., Pokrovsky V.S., Veselovsky A.V., Grishin D.V., Abakumova O.Y., Podobed O.V., Mishin A.A., Zhdanov D.D., Sokolov N.N. (2015) Identification of functional regions in the Rhodospirillum rubrum L-asparaginase by site-directed mutagenesis. Mol. Biotechnol., 57, 251-264. CrossRef Scholar google search
Покровская М.В., Покровский В.С., Александрова С.С., Анисимова Н.Ю., Андрианов Р.М., Трещалина Е.М., Пономарев Г.В., Соколов Н.Н. (2013) Рекомбинантная внутриклеточная L-аспарагиназа Rhodospirillum rubrum с низкой L-глутаминазной активностью и антипролиферативным эффектом. Биомедицинская химия, 59(2), 192-208. CrossRef Scholar google search
Малахова М.А., Покровская М.В., Александрова С.С., Соколов Н.Н., Кудряшова Е.В. (2018) Регуляция каталитической активности рекомбинантной L-аспарагиназы Rhodospirillum rubrum путём её конъюгирования с ПЭГ-хитозаном Вестник Московского университета. Серия 2. Химия, 59(4), 297-304. CrossRef Scholar google search
Karamitros C.S., Konrad M. (2014) Human 60-kDa lysophospholipase contains an N-terminal L-asparaginase domain that is allosterically regulated by L-asparagine. J. Biol. Chem., 289, 12962-12975. CrossRef Scholar google search
Rigouin C., Nguyen H.A., Schalk A.M., Lavie A. (2017) Discovery of human-like L-asparaginases with potential clinical use by directed evolution. Sci. Rep., 7, 10224. CrossRef Scholar google search
Haskell C.M., Canellos G.P. (1969) L-asparaginase resistance in human leukemia – asparagine synthetase. Biochem. Pharmacol., 18, 2578-2580. CrossRef Scholar google search
Chiu M., Taurino G., Bianchi M.G., Kilberg M.S., Bussolati O. (2019) Asparagine synthetase in cancer: beyond acute lymphoblastic leukemia. Front. Oncol., 9, 1480. CrossRef Scholar google search
Lomelino C.L., Andring J.T., McKenna R., Kilberg M.S. (2017) Asparagine synthetase: Function, structure, and role in disease. J. Biol. Chem., 292, 19952-19958. CrossRef Scholar google search
Liu W.-J., Wang H., Peng X.-W., Wang W., Liu N.-W., Wang Y., Lu Y. (2018) Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer/T-cell lymphoma in vivo and in vitro. Onco. Targets. Ther., 11, 6605-6615. CrossRef Scholar google search
Aslanian A.M., Fletcher B.S., Kilberg M.S. (2001) Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem. J., 357, 321-328. CrossRef Scholar google search
Mei L., Ontiveros E.P., Griffiths E.A., Thompson J.E., Wang E.S., Wetzler M. (2015) Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev., 29, 243-349. CrossRef Scholar google search
Aslanian A.M., Kilberg M.S. (2001) Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem. J., 358, 59-67. CrossRef Scholar google search
Hinze L., Pfirrmann M., Karim S., Degar J., McGuckin C., Vinjamur D., Sacher J., Stevenson K.E., Neuberg D.S., Orellana E., Stanulla M., Gregory R.I., Bauer D.E., Wagner F.F., Stegmaier K., Gutierrez A. (2019) Synthetic lethality of wnt pathway activation and asparaginase in drug-resistant acute leukemias. Cancer Cell, 35, 664-676.e7. CrossRef Scholar google search
Richards N.G.J., Kilberg M.S. (2006) Asparagine synthetase chemotherapy. Annu. Rev. Biochem., 75, 629-654. CrossRef Scholar google search
Chan W.-K., Horvath T.D., Tan L., Link T., Harutyunyan K.G., Pontikos M.A., Anishkin A., Du D., Martin L.A., Yin E., Rempe S.B., Sukharev S., Konopleva M., Weinstein J.N., Lorenzi P.L. (2019) Glutaminase activity of L-asparaginase contributes to durable preclinical activity against acute lymphoblastic leukemia. Mol. Cancer Ther., 18, 1587-1592. CrossRef Scholar google search
Nunes J.C.F., Cristóvão R.O., Freire M.G., Santos-Ebinuma V.C., Faria J.L., Silva C.G., Tavares A.P.M. (2020) Recent strategies and applications for L-asparaginase confinement. Molecules, 25, 5827. CrossRef Scholar google search
Ohnuma T., Holland J.F., Freeman A., Sinks L.F. (1970) Biochemical and pharmacological studies with asparaginase in man. Cancer Res., 30, 2297-22305. Scholar google search
Akbayram S., Doğan M., Akgün C., Caksen H., Oner A.F. (2010) A desensitization protocol in children with L-asparaginase hypersensitivity. J. Pediatr. Hematol. Oncol., 32, e187-e191. CrossRef Scholar google search
Pokrovskaya M.V., Pokrovsky V.S., Aleksandrova S.S., Sokolov N.N., Zhdanov D.D. (2022) Molecular analysis of L-asparaginases for clarification of the mechanism of action and optimization of pharmacological functions. Pharmaceutics, 14, 599. CrossRef Scholar google search
Li H., Yang Y., Hong W., Huang M., Wu M., Zhao X. (2020) Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct. Target. Ther., 5, 1. CrossRef Scholar google search
Anishchenko I., Pellock S.J., Chidyausiku T.M., Ramelot T.A., Ovchinnikov S., Hao J., Bafna K., Norn C., Kang A., Bera A.K., di Maio F., Carter L., Chow C.M., Montelione G.T., Baker D. (2021) De novo protein design by deep network hallucination. Nature, 600, 547-552. CrossRef Scholar google search
Evans R., Neill M.O., Pritzel A., Antropova N., Senior A., Green T., Židek A., Bates R., Blackwell S., Yim J., Ronneberger O., Bodenstein S., Zielinski M., Bridgland A., Potapenko A., Cowie A., Tunyasuvunakool K., Jain R., Clancy E., Kohli P., Jumper J., Hassabis D. (2021) Protein complex prediction with AlphaFold-Multimer. BioRxiv, 10.04.463034. CrossRef Scholar google search
Postnov V.N., Naumysheva E.B., Korolev D.V., Galagudza M.M. (2013) Nanoscale carriers for drug delivery. Biotekhnosfera, 30, 16-29. Scholar google search
Rizzari C., Citterio M., Zucchetti M., Conter V., Chiesa R., Colombini A., Malguzzi S., Silvestri D., d'Incalci M. (2006) A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica, 91, 24-31. Scholar google search
Graham M.L. (2003) Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev., 55, 1293-1302. CrossRef Scholar google search
Alpar H.O., Lewis D.A. (1985) Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. Biochem. Pharmacol., 34, 257-261. CrossRef Scholar google search
He H., Ye J., Wang Y., Liu Q., Chung H.S., Kwon Y.M., Shin M.C., Lee K., Yang V.C. (2014) Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J. Control. Release., 176, 123-132. CrossRef Scholar google search
Lorentz K.M., Kontos S., Diaceri G., Henry H., Hubbell J.A. (2015) Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase. Sci. Adv., 1, e1500112. CrossRef Scholar google search
